POSEIDA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.855 USD | +3.07% |
|
+41.95% | -13.39% |
| 12:10pm | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
| 05-01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
Chart calendar Poseida Therapeutics, Inc.
8ada955b1738fa5993ce6.VIVATtT4RWGsoNzlEyAjcqnb8BEyc5z-cxiEJ0Fc63E.GdUxKoeBLQuUlqmmeE58Fc-tunBtB6icCXbbXxBl2SR5sm0bupYLKtvomQ~d893b5d40b7861beec685c41d5f9a309
Upcoming events on Poseida Therapeutics, Inc.
Past events on Poseida Therapeutics, Inc.
| 17/04/2024 15:00 | R&D Day |
| 08/04/2024 20:30 | American Association for Cancer Research Meeting |
| 26/03/2024 20:00 | H.C. Wainwright Cell Therapy Virtual Conference - Fireside Chat |
| 07/03/2024 21:07 | Q4 2023 Earnings Release |
| 11/12/2023 02:00 | American Society of Hematology Meeting - Publication Number: 3479 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Publication Number: 1232 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Publication Number: 2293 |
| 30/11/2023 16:30 | Piper Sandler Healthcare Conference |
| 14/11/2023 13:00 | Stifel Healthcare Conference |
| 09/11/2023 21:05 | Q3 2023 Earnings Release |
| 10/10/2023 | Cell & Gene Meeting on the Mesa Conference |
| 26/09/2023 13:45 | Cantor Global Healthcare Conference |
| 12/09/2023 19:30 | H.C. Wainwright Global Investment Conference |
| 08/08/2023 21:05 | Q2 2023 Earnings Release |
| 15/06/2023 21:00 | Annual General Meeting |
| 30/05/2023 20:00 | Stifel Tailoring Genes Genetic Medicines Day |
| 19/05/2023 20:00 | American Society of Gene Cell Therapy Meeting - Abstract #1318 |
| 18/05/2023 23:00 | American Society of Gene Cell Therapy Meeting - Abstract Number: 157 |
| 18/05/2023 22:30 | American Society of Gene Cell Therapy Meeting - Abstract Number: 127 |
| 18/05/2023 20:00 | American Society of Gene Cell Therapy Meeting - Abstract #945 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 31,2 27,5 13.59% | 130 173 -24.78% | 64,7 46,4 39.58% | 52,9 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -124 -127 2.36% | -137 -120 -14.27% | -54,8 -59,6 8.13% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -127 -132 4.04% | -141 -140 -0.7% | -59,9 -48,1 -24.62% | -130 -145 10.53% | -173 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -130 -138 5.96% | -125 -148 15.61% | -63,5 -49,0 -29.58% | -123 -141 12.35% | -179 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -130 -134 3.14% | -125 -144 13.08% | -64,0 -53,0 -20.86% | -123 -141 12.33% | -179 |
|
EPS USD | Released Forecast Spread | -5,50 | -3,61 -3,10 -16.45% | -2,01 -2,30 12.46% | -0,89 -0,47 -90.04% | -1,37 -1,50 8.67% | -1,69 |
| Announcement Date | 19/06/20 | 11/03/21 | 10/03/22 | 09/03/23 | 07/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 31,2 23,1 35.08% | 1,44 0,83 72.2% | 2,70 0,93 189.29% | 116 0,83 13856.78% | 10,1 31,8 -68.34% | 10,3 3,33 210.29% | 20,0 5,09 293.57% | 9,35 18,9 -50.43% | 25,0 6,65 275.86% | 11,7 | 13,8 | 13,8 | 13,8 | 7,50 |
|
EBIT Million USD | Released Forecast Spread | -17,5 -20,8 15.97% | -57,0 -46,2 -23.17% | -41,5 -50,2 17.21% | 71,8 -48,9 246.74% | -33,2 -17,2 -93.23% | -39,5 -41,9 5.69% | -27,9 -45,9 39.38% | -36,2 -31,6 -14.61% | -25,9 -41,2 37.04% | -41,7 | -40,9 | -41,6 | -44,1 | -54,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 1,47 -21,6 106.79% | -58,1 -45,4 -27.88% | -43,0 -51,2 15.89% | 70,7 -50,0 241.23% | -33,0 -18,5 -78.04% | -38,8 -43,9 11.51% | -27,5 -47,3 42.01% | -31,7 -32,7 3.26% | -25,3 -42,7 40.65% | -42,4 | -41,6 | -42,4 | -45,0 | -57,3 |
|
Net income Million USD | Released Forecast Spread | 1,47 -21,6 106.79% | -58,1 -45,4 -27.88% | -43,0 -51,2 15.89% | 70,4 -50,0 240.72% | -33,3 -18,5 -79.62% | -38,8 -43,9 11.51% | -27,5 -47,3 42.01% | -31,8 -32,7 2.93% | -25,3 -42,7 40.65% | -42,4 | -41,6 | -42,4 | -45,0 | -57,3 |
|
EPS USD | Released Forecast Spread | 0,02 -0,35 105.76% | -0,93 -0,67 -39.85% | -0,69 -0,76 9.51% | 0,92 -0,65 241% | -0,39 0,17 -332.14% | -0,45 -0,42 -7.14% | -0,32 -0,53 39.39% | -0,35 -0,29 -19.66% | -0,27 -0,39 30.05% | -0,42 | -0,42 | -0,40 | -0,40 | -0,43 |
| Announcement Date | 10/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 09/03/23 | 09/05/23 | 08/08/23 | 09/11/23 | 07/03/24 | - | - | - | - | - |
More events
Past sector events for Poseida Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PSTX Stock
- Calendar Poseida Therapeutics, Inc.
